Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyMolecular-targeted therapy for advanced gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerPotential biomarkers for esophageal cancerTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesChanging strategies for target therapy in gastric cancerTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewPatterns of Chromosomal Aberrations in Solid TumorsAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerTwenty years of anti-HER2 therapy-associated cardiotoxicityRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesAnti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyComparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopesIgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachNovel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice.Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.Novel target for peptide-based imaging and treatment of brain tumorsPertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsDual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab eraSignalling through FOXP3 as an X-linked tumor suppressor.Energy balance, host-related factors, and cancer progression.Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registryProlonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease.Primary trastuzumab resistance: new tricks for an old drug.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentDual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsMetabolic characterization of triple negative breast cancer.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts.Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.Targeted therapy in NSCLC driven by HER2 insertionsPrognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer
P2860
Q21284978-AA7AE1A2-EDCE-4EE7-8231-AB7FDFD4EFDFQ24187006-A5E334C8-F33D-4D9A-9FB5-4C3EE7EAFCD4Q26471049-74627A3C-5E50-40A3-A01F-F9A6A596DAABQ26749416-2513463B-A11E-4FB7-A756-94F1634F633BQ26768119-1F2E612C-6B4E-4E48-9FC7-0B9CC113729CQ26774513-B5F3EFBC-7AED-4B5A-964C-D8F073DD8FF1Q26777733-6427A325-1C86-4C20-8C7C-53BD9014CD5FQ26786127-E7625BA6-DA6E-4D69-B354-FFDADA4B8217Q26797471-CBC73C15-4CB1-4488-A971-016B190DC509Q27025863-867E0678-A88C-42C1-A1C6-26D0DFBAE611Q28079391-E6357E96-8E84-40C1-8CE0-6C51DB379268Q28083123-4A35BB76-AF72-4E22-A56D-1E5C15287A27Q28235277-FDB6794C-A4B6-4897-ACA2-4C07E8F17283Q28542825-D2FAEFB3-F0A7-4395-A73A-F24FD69EAFACQ28655505-32BF3365-C6F7-41B2-8AEB-6D772C01793DQ31039304-0D9ABA1A-DBC3-4113-8E7B-AB1DC302CE5BQ33414335-FA15409B-F55F-4359-9CD1-A6AE69650479Q33519052-88E38A42-9232-4506-8616-D0E88B839C8CQ33554409-2B8B0F0A-209F-480C-AD3C-F46164924A88Q33618685-80095EC1-993B-4539-BF44-76D860F3A6E5Q33644305-DACBF7B7-6404-40B1-B571-0C223B5C2F9CQ34009045-9B83DC11-266C-4276-8BD8-E59C0F4746C5Q34062716-7D9FF6AB-7428-465B-A877-E6DAC0E9D55DQ34113130-0B2D9996-4DE6-4B49-B4D2-13D6D6D4D4CFQ34176581-3B7F7391-D02E-4F57-97F7-088B246E2A41Q34315762-11AFD99D-B566-48F8-94C8-07C3B4266E7CQ34503715-B09D98C1-B497-4FCA-94EE-9EF16D83677CQ34565743-3BB4FB73-B430-469B-8E7B-F1FFAD8371CBQ34610251-E1CC6F7C-8EB9-431B-838B-B1A90205AFA5Q34615545-110D7B3A-28A2-4379-8AEA-F924C025D1C8Q34664129-D9FA9493-55B8-4CFA-B6FE-D24D7C13DD73Q34694211-BDCA9985-DB25-4957-AD68-5ED98BE0039CQ34714574-6B9F6117-0A6B-4D3C-B89B-DBEF28EA4600Q34967995-CB3C3A41-929E-4C42-BC77-D6DBC7404D87Q34996054-4F2D33FF-8D8F-4A15-8AFF-9681252DC9B8Q35018233-16A22874-2270-4C37-B59C-39FD833D177BQ35028823-489CB7F2-8A4C-4A68-9C5D-3B7AA1FECBA3Q35031049-55EDE89C-CAE7-48A1-BCA9-8F20508B14BDQ35200528-4C6E4A85-FC79-46C9-AE3D-91F3203B35F2Q35584641-10D71985-62BE-4AB5-B2E5-634908E5B890
P2860
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@en
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@nl
type
label
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@en
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@nl
prefLabel
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@en
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@nl
P356
P1476
Understanding the mechanisms b ...... ptor 2-positive breast cancer.
@en
P2093
Kimberly L Blackwell
Neil L Spector
P304
P356
10.1200/JCO.2009.22.1507
P407
P577
2009-11-02T00:00:00Z